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Abstract
An enlarged nonlinear model for the dynamics of HIV infection and thymic
function is composed to simulate and evaluate antiretroviral therapies. In
addition to the relevant biological agents, an extra state variable is included,
associated with the thymus capacity for healthy cells production. The method-
ology contemplates eventual deleterious e¤ects of drugs over childrens thymus
recovery. The intake of RTI and PI drugs are modelled as two independent
control variables, each a¤ecting a di¤erent term in the dynamics, so extending
the prevailing pure-HAART-therapy analysis. The objective function designed
here is also more inclusive than usual, accounting for the costs of the two drug
families involved and for the thymus deterioration, in addition to penalizing
eventual virus excess and healthy cells decits. The search for the best com-
bined therapy is treated as an optimal control problem. An hybrid version of
Dynamic Programming for continuous and discrete variables is used to treat the
problem numerically. Long time-horizons are explored, aiming to avoid typical
peaks in drug prescriptions found at the beginning and end of the optimization
periods. Results indicate that certain combinations of drugs are more con-
venient than pure protocols when the value of thymus functioning is relevant,
specially for children patients.
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1 Introduction
The role of the thymus in the regeneration of healthy CD4+ T cells during
HIV infection has been widely studied in the last decade (see [11], [12] and
the references therein). It is likely that such a regenerative property is more
relevant in children [9], [10], although in all cases it is accepted that HIV presence
deteriorates thymus functioning, and therefore that the thymopoiesis at a nearly
constant rate can not be assured after the appearance of virus, specially in its
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CXCR4 version [12]. The negative e¤ect of HIV on thymus functioning is
partially reversed by the HAART therapy [3], [28], and it is also found that the
later the therapy is initiated the slower the recuperation of normal behavior will
be achieved [26]. But HAART has shown to produce severe side-e¤ects (see
[6] and its references) so it is worth to search for milder medications that still
reduce the viral load to protocol target values.
Even in the absence of virus, the thymus is one of the rst organs to un-
dergo signicant age-related degeneration, termed thymic involution. Thymic
involution results in a dramatic drop in the production of new T-cells, and is a
signicant contributing factor in immune senescence. Despite the importance
of this subject for human health, the molecular dynamics that operate in the
postnatal thymus and mediate thymic homeostasis and involution are largely
unknown [16]. Detailed mathematical models have been developed at cellular
level [14], [28], aiming to reect all relevant interactions a¤ecting the intervening
agents, to the cost of including numerous state variables, most of them di¢ cult
to measure (or to observe) continuously. According to applicable ndings of
these studies, the dynamical models used by the authors in previous publica-
tions [5], [6] were modied to include variations on healthy cellsregeneration
rate and thymus function decay. For instance, it has turned clear that the
parameter associated with the thymopoiesis in simple models should become a
state variable in itself, reecting thymic function dynamics. The new variable
declines in the presence of HIV infection [24], and this a¤ects the immune re-
sponse negatively, most in the from of a self-feeding loop. It is known that
recovery of thymic function could occur in HIV-1-infected patients on HAART.
However, specic mechanisms that contribute to this recovery are still under
study ([28], [17]).
Also it is now widely accepted that dynamic models should account for
di¤erences between children and adultsevolution of the infection and thymic
function, and also in their respective responses to medication [21], [24], [28],
[9]. In this last respect, this paper will emphasize the importance of evaluating
alternative drug families for medication, since their a¤ecting di¤erent terms or
parameters of the model will provide alternatives to standard protocols. The
evaluation of these alternatives will contemplate viral load suppression, thymic
function recovery, and medication expenses, giving rise to a combined cost func-
tional with competing individual objectives. The relative importance of these
individual objectives into the total cost, and the addition or supression of other
objectives, has been discussed in international forums [27].
The model for the dynamics together with the cost functional designed for
therapies evaluation pose an optimal control problem. This problem will adopt
a richer viewpoint in comparison with most approaches in previous papers, since
innovations are included in the model and in the evaluation functional, both con-
taining more variables and individual cost objectives. A special feature in this
last respect will be the consideration of long optimization time-horizons, in the
order of several years, in an attempt to avoid big variations in the drug doses
typically prescribed at the beginning and the end of shorter time-horizons (of
around 180 days) [6]. Another improvement in the scope of the optimization
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problem is the possibility of including two families of drugs into the medica-
tion, eventually in variable proportions. The doses admitted here will contain
typical members of the Reverse Transcriptase Inhibitors (RTI) and the protease
Inhibitors (PI) groups.
The results arising from the numerical treatment of this optimization setup
support two main conclusions: (i) a combination of RTI and PI drugs can work
better than monodrug protocols when all individual cost objectives are given
proper weight, and (ii) less aggressive drugs can partially replace HAART during
small infected children medication, especially when avoiding thymus dysfunc-
tionality is assigned a signicant value.
From the numerical simulations there arise other observations, whose precise
meaning deserve further investigation. For instance, it seems that extending
the time-horizon in optimization analyses may conduct to reliable therapies
consisting of a constant dose for each intervening drug. This outcome is positive
in avoiding big changes in therapy typically appearing at the beginning and end
of optimization periods of the order of 180 days. But the optimal required doses
become higher the longer the horizon is posed, which is not neatly positive in
several respects, not the least the increasing money-cost of the medication. A
rst interpretation would propose that higher doses are required to give more
assurance against predictable rebounds of the viral load. However, it is also true
that side-e¤ects of higher doses will increase, and that should also be included
as a partial cost in the optimization analysis, as done in previous work [6].
Unwanted e¤ects of medication were not considered in this paper due to lack of
data concerning both combined therapies and long intervals of application.
The paper is organized as follows: after the Introduction there is a Section
explaining the model for the dynamics of the control system under study, and
in Section 3 the cost functional is designed and discussed. Section 4 gives
the details of the calculation techniques used to nd optimal therapies, and
the numerical results obtained are analyzed in Section 5. The nal Section
summarizes the conclusions of the paper.
2 Dynamics of infection and thymus function
The behavior of infected patients will be modeled through a continuous-time
control system described by the following set of coupled ordinary di¤erential
equations:
_x =   x  (u1)xz
_y = (u1)xz   y
_z = (u2)y   z
_ = (u1; u2) (m   )  z
(1)
where the states are: healthy CD4+ T cells (x), infected CD4 T cells (y), free
virus copies or virions (z), and thymopoiesis rate ().
The control action over the states is exerted by the medication, i.e. by the
intake of drugs. Basically, the antiretroviral drugs can be grouped into the
following three categories ([13]):
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(i) Inhibitors of the reverse transcriptase enzyme (RTIs): If RT is inhibited,
HIV can enter a cell but will not successfully infect it; a DNA copy of the viral
genome will not be made and the cell will not make viral proteins.
(ii) Protease inhibitors (PIs): If HIV protease is inhibited, cleavage of the
viral polyprotein will not occur, and viral particles that lack functional enzymes
will be made. The net e¤ect of blocking HIV protease is that noninfectious viral
particles are made.
(iii) Fusion Inhibitors (FIs): these work by inhibiting the binding of HIV
to healthy CD4+T-cells (used in patients with multi-drug HIV resistance, not
studied in this paper).
The control variables will be restricted in this paper to u1 : dose of Zidovu-
dine AZT (RTI), and u2 : dose of Ritonavir (PI), both in [g/day] :
The rst three equations (when ; (u1) and (u2) are kept constant, as if
they were parameters) constitute a classical simplied model [18], [19], [5], thus
further comments on the meaning of their terms seem unnecessary at this time.
The last equation for  dynamics is new. It governs the natural thymus home-
ostasis. No data have been reported describing the ability of HAART agents
to cross the bloodthymus barrier and penetrate into the thymus. Therefore
the explicit dependence of the thymus variable  on any of the control variables
ui adopted in the last of Eqs. (1) should be designed as to give a reasonable
approximation to the observed qualitative behavior reported up to now. The
form adopted here includes
(u1; u2) , [1  u1(1  u2)] ; (2)
where  is a nonnegative parameter. Supposing there is no infection for the mo-
ment (z = 0; and consequently with no medication, i.e. u1 = u2 = 0; (u1; u2) =
1), and if the term (m   ) is positive (the thymus functioning is below its stan-
dard value m), then a self-induced recuperation will be intended by the human
organism, i.e. the rate _ = d=dt will increase. But the HIV infection, reected
in the present value of the state z(t) > 0; will oppose this recovering through
the term  z,  a parameter identied from: (i) the available data for thymus
dynamics showing, for instance, that the thymocytes decay to about one half of
their original number [28], [14] during the rst month after infection, together
with (ii) the conventionally accepted proportional relation between thymocytes
and CD4+ T cells. The behavior of (u1; u2) in the range of interest of the
control doses can be seen in Fig. 1. Setting
adults = 0 (3)
implies adults(u1; u2)  1 for any admissible combination of RTI and PI drugs,
coincident with the observation that for adults the thymus recovery seems to be
independent of drug e¢ ciency inside the organ [14].
Children have a better production of naive T-cells and thymocytes, which
suggests, in terms of parameters,
mchildren > madults : (4)
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Figure 1: Function (u1; u2) = [1   u1(1   u2)] acting as a coe¢ cient for the
recuperation term (m   ) in the dynamic equation for the thymic function.
Here  = children = 1:2:
But also the e¢ ciency of drugs inside the thymus is di¤erent for children and
adults. In previous work we have only considered the action of RTIs. But if
only RTI drugs are being dispensed to children patients, it is found that their
e¢ ciency inside the thymus is low [28], i.e. such a medication is not enough to
produce the same thymus recovery e¤ect than in adults (this is the explanation
for children(u1; u2) < 1 for u1 > 0, Eq. (2) and Fig. 1). The same authors
indicate that the combination with PI drugs enhances the performance of RTI
medication, and that is the reason for the term (1   u2) multiplying u1 in Eq.
(2). The combination u1(1 u2) works as a typical interactive term between
the two drugs: (1   u2) < 1 reduces the detrimental action due to u1 alone.
In order to keep 0 < children(u1; u2)  1 in the range of interest, the adopted
value for the relevant parameter was
children = 1:2 : (5)
The asymptotic value for the thymus function of an infected non medicated
patient (u1 = u2  0) will be
 , m   
z
; (6)
where the symbol z represents the ill equilibrium value of the viral load.
The point (x; y; z) =


 ;
 x
 ;
y


2 R3 describes the values approached by
the rst three state variables when the patient is critically infected and non
medicated At such values the dynamics would become asymptotically stable,
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tending to a terminal situation with _x = _y = _z = 0: By assuming that z is
approximately the same for children and for adults, the fact that the thymus
function of infected children is more susceptible of becoming dysfunctional [4],
[10] will be interpreted as the need for
children < adults ;
which in view of Eqs. (4-6) would only be possible provided that also
children > adults :
The remaining nominal values for the parameters in Eqs. (1) are then recovered
from previous versions of the model and tted to meet the di¤erences between
children and adults discussed in the text and citations above:
madults = 9 cells mm
 3day 1
mchildren = 9:5 cells mm
 3day 1
adults = 2 10 5 cells copies 1mm 3day 2
children = 6 10 5 cells copies 1mm 3day 2 (7)
 = 0:009 day 1
 = 0:3 day 1
 = 0:6 day 1
The proposed expression for (u1)
(u1)  0   1u1   2u21 (8)
was substantiated from qualitative and qualitative data in [1], [22], [25]. The pa-
rameters were estimated through standard least-squares regression techniques,
by assuming that for a short period after therapy has begun, x remains approx-
imately constant (say x(t)  ~x , x(0)). Then, the equations for _y and _z in the
model (1) become linear and their solution imply:
z(t)   k1ea1t + k2ea2t z(0) ; (9)
with coe¢ cients depending on x(0); y(0); 0; 1; 2: Data in the quoted liter-
ature, actually corresponding to treatments of recently discovered infections,
produce the following estimates
0 = 4 10 6 ml copies 1day 1 ;
1 = 0:88 10 6 ; (10)
2 = 0:3 10 6 :
Analogously, PI drugs are known to a¤ect preferentially the pseudo parame-
ter  in a form which has also been adapted to empirical data [2], [20], [23] to
obtain:
(u2)  0   3u2   4u22 ; (11)
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Figure 2: Asymptotic behavior of thymus function for infected children and
adults: (i) without medication, and (ii) under a constant pure RTI therapy in
the smaller window. Initial conditions as in Eq. (18).
0 = 8 10 2 copies cells 1day 1 ;
3 = 40:943 ; (12)
4 = 1:589 :
Some aspects of the behavior of thymus function variable  for children and
adults, in concordance with the comments above, can be visualized in Figures
2 and 3. Figure 2 also shows that, from a lower value (0) showing some
deterioration of the thymus function due to infection, its recuperation in children
is obtained after stronger oscillations than in adults, most probably due to the
childrens greater thymus volume, which allows for a quick response giving rise
to more abundant thymocytes than adults do, i.e. generating comparatively
more CD4+ T cells, able to be infected and reproducing more virus, which in
turn deteriorate thymus more signicantly, and starting the recuperation cycle
again. Perhaps this strong oscillations explain early thymus dysfunctionality
in children when not properly medicated. Figure 3 shows that combined RTI
plus PI therapies could restore thymus function in children to a higher value
and more smoothly than with pure RTI drugs. The question is what the best
proportion for such combinations is when taking a multi-objective viewpoint.
This will be attempted in the rest of the paper.
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Figure 3: Asymptotic behavior of thymus function for infected children and
adults with several constant PI therapies in addition to a constant RTI dosis
u1  0:6: Initial conditions as in Eq. (18).
3 Total cost associated to a therapeutic strategy
A typical objective functional, representing the totalcost to minimize amongst
all acceptable therapies, may be designed as follows
J(u) = Q(t0; T; x0; y0; z0; 0; u) +K(x; y; z; )T (13)
=
TZ
t0
h
a1z(t) + a2f(u1(t); u2(t)) + a3 ((t)  m)2
i
dt+ a4z
2(T ) :
This is a typical form for the objective function, consisting of a trajectory cost
Q(t0; T; x0; y0; z0; 0; u) (usually expressed as the integral of the Lagrangian
function L(x; y; z; ; u), which models the cost di¤erentials occurring during
treatment), and a nal penaltyK(x; y; z; )T associated with the departure
of the nal states from the desired (target) after therapy, which has been main-
tained quadratic (as in previous work of the authors, for eventual comparison
of results), i.e.
K(x; y; z; )T = K(x(T ); y(T ); z(T ); (T )) = a4z
2(T ) : (14)
The term a2f(u1; u2) associated with the cost of the drugs used for therapy
should be zero if medication is absent (u1 = u1 = 0). If there were no other
(positive) terms in the trajectory cost Q (see for instance [15] and some of the
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references therein), it may happen that the optimal policy result no medica-
tion. Adding state-trajectory costs (a1 and a3 not simultaneously null) will
prevent from total drug interruption at any intermediate time within optimal
therapies. Such interruptions are recognizedly inappropriate [7]. The choice
made here takes the form
L(x(t); y(t); z(t); (t); u(t))=a1z(t)+a2f(u1(t); u2(t))+a3 ((t)  m)2 (15)
The Lagrangian in this case includes the term a1z(t) penalizing the existing
of a nontrivial virus load. The values of a1 and a4;although adjustable as
all evaluation parameters, have been kept high enough as to guarantee that
the viral load descend below the 50 copies/ml in the rst 180 days for every
admissible optimal medication strategy.
The term f(u1; u2) represents the e¤ective cost of the doses prescribed by
the chosen therapy. The simplest form for the function f is just the sum of the
individual costs of each drug, i.e.
f(u1; u2) = m1u1 +m2u2 ;
with mi denoting the current price of drug ui in dollars per gram (in Argentina,
March 2011).
The coe¢ cient a3 wights the importance given to thymus deterioration in
the whole. The square in (  m)2 reects the current presumption [24] that
a too active thymus is also detrimental in curing the infection, above all in
children.
The initial time t0 is taken as zero since both the dynamics and the cost
functional are autonomous. Then the nal time T becomes the time-horizon
for the problem. A value of T  180 days was used in all calculations, in an
attempt to nd stable therapies and to avoid typical high doses at the beginning
and end of short successive optimization periods (in the order of 180 days).
The values of the coe¢ cients adopted after previous considerations were:
a1 = 0:01
a2 = 1
a3children = 100
a3adults = 50 (16)
a4 = 0:001
m1 = 15:4 dollars g
 1
m2 = 21:6 dollars g
 1
T = 420! 1200 days :
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4 Numerical treatment
4.1 Discretizing the state and control spaces
The structure of a continuous-time optimal control problem is not completely
functional to the handling of HIV medication in real life. Notwithstanding the
patients health undergoes a continuos deterioration, possibly following a model
like Equations (1), the assessment of the situation can only be made through
periodic (discontinuous) blood analyses and doctor inspections, and the present
administration of drugs can only be made through discrete amounts and changed
every some time-period according to prescriptions. This means that, even when
the system evolves in continuous time and the cost objective can theoretically
be posed in the same context, the discrete nature of:
(i) measurementsavailability or observability of the state variables (x; y; z; ),
(ii) the discrete nature of admissible control values,
(iii) the existence of restrictions in the admissible control values, which hin-
ders the smoothness of control trajectories, and
(iv) the usual delay between physician interventions and control decisions,
it is reasonable to consider a mixed continuous/discrete approach to the
numerical treatment.
In what follows, the values of the states and control variables will be then
discretized according to the following scheme
X , fxL; xL +x; xL + 2x;    ; xUg
Y , fyL; yL +y; yL + 2y;    ; yUg
Z , fzL; zL +z; zL + 2z;    ; zUg (17)
L , fL; L +; L + 2;    ; Ug
U1 , fu1L ; u1L +u1; u1L + 2u1;    ; u1U g
U2 , fu2L ; u2L +u2; u2L + 2u2;    ; u2U g
U , U1  U2
where the values of the lower (L) and upper (U ) bounds and the grid size () for
each variable should depend on real constrains on the appreciation of measure-
ment devices, the possibilities of dose subdivision, calculation capabilities, and
expectations. However it is important to note that the adopted values for yL;
zL and pL should be strictly greater than zero to avoid an unrealistic stagnation
of the variables y; z (see equation (1)). This will be further discussed, together
with the numerical trials and results.
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4.2 Hybrid Dynamic Programming
In what follows the optimal treatment of a patient with a recently discovered
infection, for instance with initial conditions near
x0 = 850 cells mm
 3 ; y0 = 41 cells mm 3 ; (18)
z0 = 3760 copies ml
 1 ; 0 = 5 cells mm 3day 1;
is illustrated. Dynamic Programming was implemented for a range of states
around these initial conditions, covering expected behaviors of the patient under
di¤erent medication strategies. The adopted discretization or spacing () of
the variables and their corresponding lower (L) and upper (U ) bounds are listed
bellow:
x = 50; y = 10; z = 500;  = 0:1; u1 = u2 = 0:2; (19)
xL = 500; yL = 1; zL = 10; L = 4; u1L = u2L = 0; (20)
xU = 1000; yU = 51; zU = 5010; U = 10; u1U = u2U = 0:8 (21)
It must be remarked that the lower thresholds yL and zL are given positive
values. This is to avoid that, after an eventual rounding of their values, the
discretized trajectories reach any point with y = z = 0; since in that case the
optimal strategy would continue with u  0 till the end, which is certainly
erroneous (and dangerous). Indeed, the real system never reaches y = z =
 = 0 from an initial condition di¤erent from the unstable equilibrium, which
means that any remaining infection (y > 0; z > 0) will grow if u = (0; 0) and
this growth should eventually be controlled with some ui > 0.
The upper limits u1U = u2U = 0:8 adopted for the drug doses contemplate
the protocols based on each pure component: the standard dosis for RTI alone
is **********
The cost takes now a slightly di¤erent form
J (u) ,
T=hX
k=0
tk+1Z
tk
h
a1z(t) +m1u1(t) +m2u2(t) + a3 ((t)  m)2
i
dt+ a4 (z(T=h)  z^)2 ;
(22)
tk , t0 + hk ;
where x(t); y(t); z(t); (t) must be understood, in each interval [tktk+1) ; as the
rounded result of the state-transition function (t; t0; x; y; z; ; u(:)) associated
with the continuous-time model (1), namely
(x(t); y(t); z(t); (t))
0
= (t; tk; xk; yk; zk; k; ~uk) ; (23)
(xk+1; yk+1; zk+1; k+1)
0
= round ((tk+1; tk; xk; yk; zk; k; ~uk)) ; (24)
the symbol ~uk being interpreted as the piecewise-constant control trajectory
u(t) = (u1(t); u1(t)) , ~uk(t)  uk = (u1k ; u2k) 2 U 8t 2 [tktk+1) ; (25)
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and where round acts over the values (x(tk+1); y(tk+1); z(tk+1); (tk+1))
0
=
(tk+1; tk; xk; yk; zk; k; ~uk) in a safeway, precisely
xk+1 , closest smaller value next to x(tk+1) in X
yk+1 , closest bigger value next to y(tk+1) in Y
zk+1 , closest bigger value next to z(tk+1) in Z (26)
k+1 , closest value next to (tk+1) in L
This means that, even when the time, state, and control spaces are dis-
cretized, the values of the states at a time tk+1 are calculated by integrating
the continuous-time dynamics of the control system (i.e. through the state-
transition function  of the system) by using the known states at time tk as ini-
tial conditions, and then rounding the states resulting from integration. That
explains the adjective Hybrid assigned to the Dynamic Programming tech-
nique used as numerical approach to the problem in this paper. The adopted
value of h = 30 days takes into consideration the observed peak time(of ap-
proximately 20 days) occurring in the state variables and sensitivities (see [5]).
The possibility of a hiding acute infection period is discarded this way, since at
least the results of a blood analysis reecting the situation will come at some
intermediate point.
5 Numerical results
The rst calculations made were for adult patients, from initial conditions as
in Eq. (18), resulted in an optimal control strategy as shown in Fig. 4. The
optimal doses of RTI stabilized at 0.6 g after the critical period of 180 days,
while PI did the same at 0.4 g. This was a good result is some aspects: rst,
both drugs were present in a nontrivial combination at all stages; and second,
both of them stayed at a constant level from more than the last half of the period
of consideration, which suggests that the medication uadults(t)  (0:6; 0:4) could
become safe for approximately t > 180 days, without need to repeat calculations
for successive optimization periods. But the preference for RTIs over PIs was
somewhat expected since u1 acts by diminishing directly both the viral load
and the thymus function dysfunctionality (and consequently lowering the costs
weighted by a1, a3, and a4), while increasing the drug cost weighted by a2 at
a lower rate than u2 does (PIs are more expensive). This result is reinforced
when the cost of thymus illness is not given preponderance in the composition
of the cost, as was decided to be the case for adults.
Things change for children, as can be seen in Fig. 8, due to the di¤erent
set of parameters used in calculations, as indicated in Eqns. (7, 16). The
optimal medication for children stabilizes at uchildren(t)  (0:4; 0:6) for t > 180
days, reversing the roles of RTI and PI in the optimal therapy for adults. This
shows that an alternative combination of drugs, less agressive to the thymus
functioning in children, can result optimal when the weights of the partial costs
are tuned as to reect a comprehensive evaluation of the situation.
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Figure 4: Optimal strategy (therapy) for adults, amongst all admissible combi-
nations of RTI and PI drugs. Optimization horizon T = 420 days.
a3
R
a1z(t)dt
R
a3( m)2dt
R
m1u1dt
R
m2u2dt
C o s t o f
m e d ic a t io n
children
adults
30
476.30
416.81
16622
8253
2495(0:4)
3142(0:6)
3889(0:4)
1814(0:2)
6383
4956
children
adults
100
393.72
309.90
53546
25493
2495(0:4)
3788(0:6)
5184(0:6)
3888(0:4)
7679
7676
Table 1: Cost values for children and adult treatments for a3 = 30; 100;T = 420
days. The asymptotic optimal value of the drug ui appears as a superscript of
the partial cost associated with such ui.
The state trajectories for x(t); z(t) and (t); corresponding to the optimal
control strategies, both dor adults and children, are depicted in Figs. 5-7. They
show a very acceptable performance, judging from common-sense expectations
for a good medication, i.e. it should quickly abate viral load while at the same
time recuperates healthy cells and thymus function. For illustration purposes,
and only in the adultscase, curves for the values of the states x; z;  that are
generated in the intermediate calculations of the optimal control strategy by the
Dynamic Programming scheme are added in Figs. 5-7. These values, obtained
after applying the rounding conventions announced in Eqs. (26), are shown to be
conservative, since the continuous-line curves (real behavior of the patient due
to optimal medication) tend to the desired values more quickly and accurately
than the remaining ones (Dynamic Programming rounded approximations).
Partial costs due to optimal medications in children and adult patients are
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Figure 5: x-trajectories for children and adults resulting from their correspond-
ing optimal medications. x-values used in Dynamic Programming calculations
are also shown for adults.
0 50 100 150 200 250 300 350 400
0
500
1000
1500
2000
2500
3000
3500
4000
Time (days)
V
ira
l l
oa
d 
(c
op
ie
s/
m
L)
Optimal trajectory (adult patient)
Rounded trajectory (adult patient)
Dynamic programming values (adult patient)
Optimal trajectory (pediatric patient)
Figure 6: z-trajectory for children and adults resulting from their corresponding
optimal medications. z-values used in Dynamic Programming calculations are
also shown for adults.
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Figure 7: -trajectories for children and adults resulting from their correspond-
ing optimal medications. -values used in Dynamic Programming calculations
are also shown for adults.
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Figure 8: Optimal strategy (therapy) for children, amongst all admissible com-
binations of RTI and PI drugs. Optimization horizon T = 420 days.
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Figure 9: z-trajectory for children resulting from optimal combined RTI plus PI
medications corresponding to di¤erent weights a3 assigned to thymusdeciency
cost.
shown in Table 1, for a3 = 30 and a3 = 100: In both cases the sum of the
asymptotic optimal doses is the same for children and adults, although for a3 =
100 such a sum is higher (1 g instead of 0.8 g for a3 = 30); indicating that
more concern for thymus function will require more drug all other objectives
equally weighted. The cost of medication for children when a3 = 30 is 1.28
times the cost for adults, but this is not too expensive to pay for as much as
16622=8253 = 2: 014 1 times the all along deviation of the thymus function. For
a3 = 100 this argument is even stronger but the cost of medication rises both
for children and adults to reach around 7680 dollars in 420 days. As a3chiildren
increases the recommended PI dosis increases and surpasses the one for RTIs.
This could be rephrased by saying that emphasizing thymus concern in children
patiens would amount to use increasing proportion of PI drugs replacing RTIs.
This policy would be reinforced if the hypothesis of PI retarding the switching
time from R5 a X4 virus [8] is conrmed by further empirical data.
For longer optimization horizons things become more complex. Figures 9,
10 depict respectively the z- and -trajectories corresponding to the optimal
medications calculated for children and a very long T (=1200 days), using dif-
ferent values for a3: The asymptotic recommended drug doses are higher than
for shorter optimization periods, explained by the need to avoid signicant re-
bounds in the viral load. This is an issue that deserve further study, above
all considering that model parameters are no longer to be trusted to remain
constant after such long periods of treatment, and the same can be expected
of the partial cost weights. Perhaps long optimizarion horizons would require
then nonautonomous formulations for both the dynamics and the cost function.
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Figure 10: -trajectory for children resulting from optimal combined RTI plus PI
medications corresponding to di¤erent weights a3 assigned to thymusde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cost.
6 Conclusions
A methodology, suitable for assessing drug combinations in HIV treatment of
children and adult patients, has been presented. The problem was posed in
the context of deterministic optimal control, although there are at present un-
certainties concerning the dynamics of human thymus under viral infection and
highly active medication than would probably require an stochastic setup in
the future. It has been found that, providing the model be accurate enough,
di¤erent drug combinations could result better than monotherapies, and that
the best combinations are not completely obvious but discovered through math-
ematical analysis and numerical calculation. The choice for the dosis of two
di¤erent drugs was to be determined every 30 days, and are to be taken con-
stantly during the next period. The criteria for deciding what was best were a
number of conicting objectives as partial terms of a cost functional entailing
evaluations during the whole optimization time-horizon and at the end of it.
Classical Dynamic Programming proved to be useful, after proper adapting to
the mixed continuous-discrete characteristics of the problem, in nding optimal
medication strategies amongst so many degrees of freedom.
The problem had essentially two di¤erent setups: one for adult patients
and another one for just-born children. Parameters for the dynamics and the
evaluation functional of each setup were tuned to reect existing knowledge,
which is still little more than incipient. But results are promising: an inverse
tendency in the proportion between the RTI and PI families of drugs seem to
be recommendable for children in comparison with that for adults. These is to
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say: more PIs than RTIs for children, and the converse ratio for adults, when
the concern for thymus function grows in appreciation with respct to other cost
objectives. Another positive outcome is the stabilization of the composition of
the optimal dosis after some 180 days towards a mix with signicant PI share.
This is regarded as milder acceptable therapies, especially well received by
children patients.
The variations of optimal medication strategies were also assessed when eval-
uating long periods, the increasing of the total amount of drugs being the ex-
pected consecuence of minimizing rebound risks for viral load. But it has to be
recalled that no consideration of side-e¤ects have entered the present method-
ology. Again, the longer the horizon under study, the greater the uncertainties
are in the number and values of parameters and weight coe¢ cients needed for
a denitive problem formulation.
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